WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing) (WOEST)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00769938 |
Recruitment Status :
Completed
First Posted : October 9, 2008
Last Update Posted : January 15, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Anticoagulants Platelet Aggregation Inhibitors Stents Atrial Fibrillation | Device: PCI (percutaneous coronary intervention) | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 573 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing |
Study Start Date : | December 2008 |
Actual Primary Completion Date : | August 2012 |
Actual Study Completion Date : | August 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Aspirin + clopidogrel + oral anticoagulation |
Device: PCI (percutaneous coronary intervention)
only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment |
Active Comparator: Oral anticoagulants + clopidogrel |
Device: PCI (percutaneous coronary intervention)
only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment |
- The combined end point of minor, moderate or major bleeding complications during the initial hospitalization & one year follow-up. (TIMI & GUSTO criteria). [ Time Frame: 1 year ]
- The combined event of death, myocardial infarction, stroke, systemic embolization & target vessel revascularisation and the individual components of the composite primary and secondary endpoints. [ Time Frame: 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients is on oral anticoagulation therapy and this will be continued throughout the period of 1 year-and deployment of at least 1 coronary stent (bare metal stent (BMS) or drug eluting stent (DES)). -age of more than 18 years
Exclusion Criteria:
- cardiogenic shock,
- contra-indication for aspirin or clopidogrel
- allergy to aspirin or clopidogrel,
- documented peptic ulcer disease within the previous six months,
- pregnancy and
- previous intracerebral haemorrhage or
- significant thrombocytopenia (platelet count < 50x10 9/L).
- major bleeding according to timi criteria within the past 12 months
- age > 80 years

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00769938
Belgium | |
OLV Aalst | |
Aalst, Belgium | |
UZ Antwerpen | |
Antwerpen, Belgium | |
ZOL | |
Genk, Belgium | |
Maria Middelares | |
Gent, Belgium | |
UZ KU Leuven | |
Leuven, Belgium | |
Netherlands | |
MCA Alkmaar | |
ALkmaar, Netherlands | |
Academisch Medisch Centrum Amsterdam | |
Amsterdam, Netherlands | |
OLVG | |
Amsterdam, Netherlands | |
Amphia Ziekenhuis | |
Breda, Netherlands | |
Catharina Ziekenhuis | |
Eindhoven, Netherlands | |
UMCG | |
Groningen, Netherlands | |
Sint Antonius Ziekenhuis | |
Nieuwegein, Netherlands, 3435 CM | |
Zuiderziekenhuis | |
Rotterdam, Netherlands | |
Twee Steden Ziekenhuis | |
Tlibrug, Netherlands | |
Isala klinieken | |
Zwolle, Netherlands |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | W. Dewilde, Dr, R&D Cardiologie |
ClinicalTrials.gov Identifier: | NCT00769938 |
Other Study ID Numbers: |
RDC-2008-03 |
First Posted: | October 9, 2008 Key Record Dates |
Last Update Posted: | January 15, 2013 |
Last Verified: | January 2013 |
Atrial fibrillation Percutaneous coronary stenting Bleeding complications Triple therapy |
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |